Sue is a clinical research professional who received her BA in psychology from the University of Notre Dame and later completed a BSN at Oakland University. Prior to entering the drug development industry, Sue practiced psychiatric nursing in a range of settings including inpatient, outpatient, psychiatric E.R., and case management. With multidisciplinary treatment and research teams, she focused on the care and treatment of patients with chronic mental illness and managed care for highly recidivistic patients with schizophrenia in specialized Assertive Community Treatment (ACT) programs in Oakland County, MI and San Diego County, CA.
Sue transitioned from nursing to clinical research in 1991 and has broad experience in monitoring, clinical management, project and program management in Phases I-III clinical trials. She has worked within both pharmaceutical and CRO organizations in managing large, complex, full-scope, global clinical trials with a focus in Alzheimer’s disease, bipolar disorder, depression, panic disorder, schizophrenia, multiple sclerosis, Parkinson’s disease psychosis and stroke.
Prior to joining the NeuraWell team, Sue’s recent work included program management with Intra-Cellular Therapies on the development of Caplyta (lumateperone) for schizophrenia and bipolar depression, and at ACADIA Pharmaceutical’s development of NUPLAZID (pimavanserin) for Parkinson’s disease psychosis.